Cambrian Bio
New York, US · Founded 2019 · Delaware corporation · 30 employees on LinkedIn · 8 known investors
Find your way into Cambrian Bio
559 people in our graph share verified history with the Cambrian Bio team — schools, employers, funds. One of them is your warm intro.
Kike Mirallesunlockedknows James Peyer, PhD · together at McKinsey & Company (overlapped)
×11knows the team · via McKinsey & Company
Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
Founders & leadership
Cambrian Bio was founded in 2019 by James G. Peyer, James Peyer, and James Peyer, PhD.
JG
James G. PeyerinFounder & CEOJames G. Peyer founded Cambrian Bio, a clinical-stage drug development company developing therapeutics targeting metabolic pathways associated with aging. He previously founded Apollo Ventures, a longevity therapeutics company builder, and completed a PhD in blood stem cell biology at UT Southwestern as an NSF Fellow.
JP
James PeyerinCEO, Founder, Board DirectorJames Peyer is founder and CEO of Cambrian Bio, a clinical-stage drug development company creating therapeutics targeting metabolic pathways such as AMPK and mTOR. Previously, he founded and served as CEO of Apollo Ventures, a company builder focused on longevity therapeutics, and completed a PhD in blood stem cell biology at UT Southwestern as an NSF Fellow.
JP
James Peyer, PhDinFounder & CEOJames Peyer is Founder and CEO of Cambrian Bio, a drug development company targeting metabolic pathways implicated in aging. He previously founded Apollo Ventures, a longevity therapeutics company builder, and completed his PhD in blood stem cell biology at UT Southwestern as an NSF Fellow.
MN
Mark NuttallinChief Business Officer
RT
Ruth Thieroff-EkerdtinEVP Clinical Development
WD
William DeVaulinChief Legal Officer
BD
Bill DeVaulinChief Legal Officer
Board
CA
Christian Angermayerin𝕏Chairman, Co-Founder, Board DirectorFounder and Chairman of the Board at atai Life Sciences
MS
CA
Christian AngermeyerBoard director
PF-modified.png)
Paul FarrBoard director
JH
Juliette HanChief Financial Officer & Chief Operating Officer
Investors · 8
Reported raises · per SEC filings
Form D private placements$272.2M disclosed across 5 rounds · 2019–2026
▶$123.8MraisedJul 2026 · 80 investors · BiotechnologyRule 506(c)
▶$123.8MraisedJul 2026 · 80 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- James PeyerExecutive Officer, Director
- Juliette HanExecutive Officer, Director
- Mark NuttallExecutive Officer
- Ruth Thieroff-EkerdtExecutive Officer
- William DeVaulExecutive Officer
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Brenton L. SaundersDirector
- Paul FarrDirector
- Martin GunhagaDirector
- Lorin Van NulandDirector
- Offering amount
- $129.8M
- Amount sold
- $123.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$23MraisedJan 2025 · 30 investors · PharmaceuticalsRule 506(b)
▶$23MraisedJan 2025 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- Paul FarrDirector
- James G. PeyerExecutive Officer, Director
- Brenton SaundersDirector
- Offering amount
- $37.6M
- Amount sold
- $23M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedDec 2021 · 56 investors · PharmaceuticalsRule 506(b)
▶$92.2MraisedDec 2021 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $100.8M
- Amount sold
- $92.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$28.4MraisedMay 2021 · 30 investors · PharmaceuticalsRule 506(b)
▶$28.4MraisedMay 2021 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James G. PeyerExecutive Officer, Director, Promoter
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Offering amount
- $28.4M
- Amount sold
- $28.4M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.8MraisedJan 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermeyerDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Cambrian Bio mafia →7 people who came through Cambrian Bio went on to found or lead other companies.
Christian AngermayerChairman, Co-Founder, Board DirectorFounded Apeiron Investments +1James Peyer, PhDExecutive Officer, DirectorFounded Rapalogix Health +1Maryanna SaenkoDirectorFounded Future VenturesViktoriya TigipkoSeed InvestorFounded TA VenturesJuliette HanCFO COO I Director, BODFounded Two SigmaSebastian BrunemeierCIO & Co-FounderFounded Cyclone TherapeuticsShalini GuptaProduct ConsultantFounded Asima Health Inc. Website
Competitors · 2
by search overlap
Bridgebio25 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Cambrian Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cambrian Bio do?
- Cambrian Bio is a clinical-stage drug development company creating precision therapeutics that target metabolic pathways which decline with age, such as AMPK and mTOR. Its lead asset, ATX-304, is an AMPK Network Activator being developed for obesity and prediabetes.
- Who founded Cambrian Bio?
- Cambrian Bio was founded by James G. Peyer, James Peyer, James Peyer, PhD in 2019.
- Who are Cambrian Bio's investors?
- Cambrian Bio's investors include Catalio Capital Management, LP, Future Ventures, Khosla Ventures, Korify Capital, Sprint Vc, Strawberry Creek Ventures, TA Ventures, atai Life Sciences.
- How much funding has Cambrian Bio raised?
- Cambrian Bio has disclosed $272.2M raised across 5 rounds.
- Where is Cambrian Bio headquartered?
- Cambrian Bio is headquartered in New York, US.